The U.S. government awarded Novavax, Inc. (NASDAQ: NVAX) $1.6 billion in funding to support its COVID-19 vaccine, and the company is confident it has the capability to produce 100 million doses by the end of the year, Novavax CEO Stanley Erck said on CNBC's "Squawk Box."
Novavax On Track For 100M Doses: Novavax got straight to work on a vaccine in January as soon as the gene sequencing of the virus was first identified, Erck said.
The company was quick to use a manufacturing platform similar to other vaccines to scale up, the CEO said.
The government grant as part of Operation …
Full story available on Benzinga.com